Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 23;13(1):15932.
doi: 10.1038/s41598-023-42911-7.

Prevalence and predictors of post-abortion modern contraceptive utilization among reproductive age women in Ethiopia

Tadele Biresaw Belachew  1 , Wubshet Debebe Negash  2 , Desale Bihonegn Asmamaw  3 , Samrawit Mihret Fetene  2 , Banchlay Addis  2 , Tsegaw Amare Baykeda  2   4 , Atitegeb Abera Kidie  5 , Abel Endawkie  6 , Alebachew Ferede Zegeye  7 , Tadesse Tarik Tamir  8 , Elsa Awoke Fentie  3 , Sisay Maru Wubante  9
Affiliations

Prevalence and predictors of post-abortion modern contraceptive utilization among reproductive age women in Ethiopia

Tadele Biresaw Belachew et al. Sci Rep. .

Abstract

The development of a post-abortion family plan is an integral part of comprehensive abortion care. In spite of this, it received insufficient attention as a means of breaking the cycle of repeated abortions, unintended pregnancies, and maternal deaths resulting from abortion. Therefore, this study examined post abortion modern contraceptive utilization among Ethiopian women as well as associated factors. The study was based on secondary data analysis of the Ethiopian Demographic and Health Survey 2016 data. A total weighted sample of 1236 reproductive age women was included. A multilevel mixed-effect binary logistic regression model was fitted to identify the significant associated factors of post abortion contraceptive use. Statistical significance was determined using Adjusted Odds Ratio (AOR) with 95% confidence interval. Overall prevalence of post abortion contraceptive use was observed to be 25.6% (95% CI: 23.24, 28.12). Women's age 15-24 (AOR = 2.34; 95% CI: 1.11, 4.93), and 25-34 (AOR = 1.94; 95% CI: 1.27, 2.98), married women (AOR = 2.6; 95% CI: 1.43, 4.96), women who had 1-4 (AOR = 4.13; 95% CI: 1.79, 9.57) and ≥ 5 number of children (AOR = 8.80; 95% CI: 3.30, 13.49), Being in metropolitan region (AOR = 9.14; 95% CI: 1.79, 12.48), women being in urban area (AOR = 1.85; 95% CI: 1.32, 2.24), and community media exposure (AOR = 1.75; 95% CI: 1.11, 3.56) were associated with post abortion modern contraceptive use. Post abortion modern contraceptive use in this study was low. Women age, current marital status, number of living children, residency, community media exposure, and region were significantly associated with post abortion modern contraceptive utilization. Therefore, it is better to provide ongoing health information about post-abortion family planning and its benefits, especially for people who live in rural and small peripheral regions, and public health policymakers should take both individual and community level factors into account when designing family planning programmes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Prevalence of post abortion modern contraceptive utilization in Ethiopia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. WH Organization. Handbook on Health Inequality Monitoring: With a Special Focus on Low-and Middle-Income Countries. (World Health Organization, 2013).
    1. WH Organization. WHO Recommendations for Augmentation of Labour. (World Health Organization, 2014). - PubMed
    1. Huber D, Curtis C, Irani L, Pappa S, Arrington L. Postabortion care: 20 years of strong evidence on emergency treatment, family planning, and other programming components. Glob. Health Sci. Pract. 2016;4(3):481–494. - PMC - PubMed
    1. Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon®) BMJ Sex. Reprod. Health. 2005;31(1):67–70. - PubMed
    1. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E, et al. Implanon® versus medroxyprogesterone acetate: Effects on pain scores in patients with symptomatic endometriosis—A pilot study. Contraception. 2009;79(1):29–34. - PubMed

Substances